ProtoKinetix, Incorporated (PKTX)
USD 0.01
(0.51%)
USD 0.01
(0.51%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -367.22 Thousand USD | 80.14% |
| 2022 | -1.84 Million USD | 20.52% |
| 2021 | -2.32 Million USD | 69.56% |
| 2020 | -7.64 Million USD | -82.16% |
| 2019 | -4.19 Million USD | -245.82% |
| 2018 | -1.21 Million USD | 19.61% |
| 2017 | -1.5 Million USD | 0.83% |
| 2016 | -1.52 Million USD | -20.39% |
| 2015 | -1.26 Million USD | -228.98% |
| 2014 | 215.69 Thousand USD | 9.0% |
| 2013 | -26.4 Thousand USD | -143.87% |
| 2012 | -173.11 Thousand USD | 85.81% |
| 2011 | -1.21 Million USD | 10.61% |
| 2010 | -1.36 Million USD | -9.52% |
| 2009 | -1.24 Million USD | 19.63% |
| 2008 | -1.52 Million USD | 42.9% |
| 2007 | -2.71 Million USD | -38.91% |
| 2006 | -1.95 Million USD | 56.97% |
| 2005 | -4.81 Million USD | 15.32% |
| 2004 | -5.36 Million USD | -253.57% |
| 2003 | -1.51 Million USD | -10098.58% |
| 2002 | -14.87 Thousand USD | 11.97% |
| 2001 | -16.9 Thousand USD | -48191.43% |
| 2000 | -35.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -72.06 Thousand USD | 10.73% |
| 2024 Q1 | -80.71 Thousand USD | 17.36% |
| 2023 Q2 | -104.01 Thousand USD | -7.97% |
| 2023 Q1 | -96.33 Thousand USD | 81.74% |
| 2023 FY | - USD | 80.14% |
| 2023 Q3 | -69.2 Thousand USD | 33.47% |
| 2023 Q4 | -97.66 Thousand USD | -41.12% |
| 2022 Q1 | -516.84 Thousand USD | -31.38% |
| 2022 Q2 | -441.4 Thousand USD | 14.6% |
| 2022 FY | - USD | 20.52% |
| 2022 Q4 | -527.45 Thousand USD | -42.83% |
| 2022 Q3 | -369.29 Thousand USD | 16.34% |
| 2021 FY | - USD | 69.56% |
| 2021 Q1 | -132.32 Thousand USD | 77.23% |
| 2021 Q2 | -402.98 Thousand USD | -204.54% |
| 2021 Q3 | -1.4 Million USD | -247.72% |
| 2021 Q4 | -393.4 Thousand USD | 71.93% |
| 2020 Q4 | -581.06 Thousand USD | 65.55% |
| 2020 Q3 | -1.68 Million USD | 23.51% |
| 2020 Q2 | -2.2 Million USD | 30.4% |
| 2020 Q1 | -3.16 Million USD | -29.14% |
| 2020 FY | - USD | -82.16% |
| 2019 Q2 | -768.5 Thousand USD | -101.36% |
| 2019 FY | - USD | -245.82% |
| 2019 Q1 | -381.66 Thousand USD | -95.04% |
| 2019 Q3 | -590.99 Thousand USD | 23.1% |
| 2019 Q4 | -2.45 Million USD | -315.17% |
| 2018 Q2 | -340 Thousand USD | -12.12% |
| 2018 Q1 | -303.25 Thousand USD | 40.48% |
| 2018 Q3 | -371.02 Thousand USD | -9.12% |
| 2018 Q4 | -195.68 Thousand USD | 47.26% |
| 2018 FY | - USD | 19.61% |
| 2017 Q3 | -298.34 Thousand USD | 7.38% |
| 2017 FY | - USD | 0.83% |
| 2017 Q1 | -374.66 Thousand USD | -0.18% |
| 2017 Q2 | -322.12 Thousand USD | 14.02% |
| 2017 Q4 | -509.51 Thousand USD | -70.78% |
| 2016 Q1 | -344.1 Thousand USD | 28.76% |
| 2016 Q2 | -370.03 Thousand USD | -7.53% |
| 2016 Q3 | -431.32 Thousand USD | -16.56% |
| 2016 Q4 | -373.99 Thousand USD | 13.29% |
| 2016 FY | - USD | -20.39% |
| 2015 Q1 | -257.3 Thousand USD | -38.9% |
| 2015 Q4 | -483.03 Thousand USD | -105.63% |
| 2015 Q3 | -234.9 Thousand USD | 19.04% |
| 2015 Q2 | -290.12 Thousand USD | -12.75% |
| 2015 FY | - USD | -228.98% |
| 2014 Q4 | -185.24 Thousand USD | -191.99% |
| 2014 Q3 | -63.44 Thousand USD | -6.18% |
| 2014 Q2 | -59.74 Thousand USD | 21.12% |
| 2014 Q1 | -75.74 Thousand USD | 52.31% |
| 2014 FY | - USD | 9.0% |
| 2013 FY | - USD | -143.87% |
| 2013 Q2 | -88.68 Thousand USD | -7.09% |
| 2013 Q4 | -158.81 Thousand USD | -72.88% |
| 2013 Q3 | -91.86 Thousand USD | -3.59% |
| 2013 Q1 | -82.81 Thousand USD | -94.62% |
| 2012 Q2 | -33.48 Thousand USD | 44.53% |
| 2012 Q3 | -38.22 Thousand USD | -14.17% |
| 2012 Q4 | -42.55 Thousand USD | -11.31% |
| 2012 FY | - USD | 85.81% |
| 2012 Q1 | -60.35 Thousand USD | 94.67% |
| 2011 Q2 | -186.65 Thousand USD | -187.22% |
| 2011 Q1 | 213.99 Thousand USD | 154.88% |
| 2011 Q3 | -115.4 Thousand USD | 38.17% |
| 2011 FY | - USD | 10.61% |
| 2011 Q4 | -1.13 Million USD | -880.78% |
| 2010 Q1 | -167.12 Thousand USD | 75.36% |
| 2010 Q3 | -582.78 Thousand USD | -188.02% |
| 2010 Q4 | -389.93 Thousand USD | 33.09% |
| 2010 FY | - USD | -9.52% |
| 2010 Q2 | -202.33 Thousand USD | -21.07% |
| 2009 Q1 | -122.88 Thousand USD | 26.51% |
| 2009 Q4 | -678.21 Thousand USD | -147.53% |
| 2009 Q3 | -273.98 Thousand USD | -60.21% |
| 2009 FY | - USD | 19.63% |
| 2009 Q2 | -171.02 Thousand USD | -39.17% |
| 2008 FY | - USD | 42.9% |
| 2008 Q3 | -429.51 Thousand USD | 29.49% |
| 2008 Q4 | -167.21 Thousand USD | 61.07% |
| 2008 Q2 | -609.15 Thousand USD | -83.19% |
| 2008 Q1 | -332.51 Thousand USD | 71.37% |
| 2007 Q1 | -286.11 Thousand USD | -291.13% |
| 2007 Q4 | -1.16 Million USD | -15.29% |
| 2007 Q3 | -1 Million USD | -287.58% |
| 2007 Q2 | -259.96 Thousand USD | 9.14% |
| 2007 FY | - USD | -38.91% |
| 2006 Q2 | -1.57 Million USD | -643.98% |
| 2006 Q1 | -212.32 Thousand USD | 76.93% |
| 2006 Q3 | -300.59 Thousand USD | 80.97% |
| 2006 Q4 | 149.69 Thousand USD | 149.8% |
| 2006 FY | - USD | 56.97% |
| 2005 Q3 | -66.52 Thousand USD | 98.12% |
| 2005 Q4 | -920.2 Thousand USD | -1283.18% |
| 2005 FY | - USD | 15.32% |
| 2005 Q2 | -3.53 Million USD | -1152.77% |
| 2005 Q1 | -282.25 Thousand USD | 91.72% |
| 2004 FY | - USD | -253.57% |
| 2004 Q3 | -222.71 Thousand USD | 67.31% |
| 2004 Q2 | -681.3 Thousand USD | 35.29% |
| 2004 Q1 | -1.05 Million USD | 15.56% |
| 2004 Q4 | -3.4 Million USD | -1430.38% |
| 2003 Q4 | -1.24 Million USD | -381.37% |
| 2003 Q3 | -259 Thousand USD | -7493.08% |
| 2003 FY | - USD | -10098.58% |
| 2003 Q2 | -3411.00 USD | 0.0% |
| 2002 FY | - USD | 11.97% |
| 2001 FY | - USD | -48191.43% |
| 2001 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.483% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 93.806% |
| SQZ Biotechnologies Company | -64.14 Million USD | 99.427% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 97.886% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.391% |
| Mesoblast Limited | -62.38 Million USD | 99.411% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 76.093% |
| Genus plc | 73.7 Million USD | 100.498% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 94.446% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 89.647% |
| Marizyme, Inc. | -34.28 Million USD | 98.929% |
| ContraFect Corporation | -64.99 Million USD | 99.435% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 95.814% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 91.887% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 73.804% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 86.114% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 84.198% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 29.114% |
| Accustem Sciences Inc. | -3.74 Million USD | 90.198% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 99.239% |
| EV Biologics, Inc. | -1.26 Million USD | 71.02% |
| Q BioMed Inc. | -617.62 Thousand USD | 40.543% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 110.281% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 41.933% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 83.925% |
| Biomind Labs Inc. | -1.03 Million USD | 64.504% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 103.718% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 94.872% |
| Skye Bioscience, Inc. | -13.54 Million USD | 97.289% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 75.311% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -1368.884% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 90.546% |
| IMV Inc. | -35.52 Million USD | 98.966% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 97.686% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 85.323% |
| GB Sciences, Inc. | -1.41 Million USD | 74.137% |
| Alpha Cognition Inc. | -9.7 Million USD | 96.216% |
| HST Global, Inc. | -5303.00 USD | -6824.778% |
| CSL Limited | 4.78 Billion USD | 100.008% |
| Halberd Corporation | -74.27 Thousand USD | -394.381% |
| Enzolytics Inc. | -2.12 Million USD | 82.695% |
| Resverlogix Corp. | -11.74 Million USD | 96.873% |
| Affymax, Inc. | -14.29 Million USD | 97.431% |
| SYBLEU INC | -141.57 Thousand USD | -159.39% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 88.011% |
| argenx SE | -216.02 Million USD | 99.83% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 99.336% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 130.174% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 75.501% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 196.932% |
| AVAX Technologies, Inc. | -6.11 Million USD | 93.992% |
| Zenith Capital Corp. | -8.6 Million USD | 95.733% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.852% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2007.921% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 84.99% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -108.619% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 99.074% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 87.304% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 64.903% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 5561.347% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 79.016% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 80.883% |
| BioStem Technologies, Inc. | -7.55 Million USD | 95.138% |
| ONE Bio Corp. | 13.61 Million USD | 102.698% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -102.786% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 82.148% |
| Agentix Corp. | -1.37 Million USD | 73.23% |
| LadRx Corporation | 412.28 Thousand USD | 189.07% |
| Cell Source, Inc. | -4.27 Million USD | 91.405% |
| Regen BioPharma, Inc. | 1.46 Million USD | 125.05% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 60.807% |
| NovAccess Global Inc. | -1.03 Million USD | 64.513% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 104.148% |
| Itoco Inc. | -1.86 Million USD | 80.352% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 3.266% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 67.095% |
| Kadimastem Ltd | -2.62 Million USD | 86.007% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -53.553% |
| CytoDyn Inc. | -18.02 Million USD | 97.963% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -364.666% |
| Mobile Lads Corp. | -2.24 Million USD | 83.615% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -2902.87% |
| Qrons Inc. | -40.08 Thousand USD | -816.197% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 24.39% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 169.624% |
| Rebus Holdings, Inc. | -951 Thousand USD | 61.386% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 65.422% |
| International Stem Cell Corporation | 202 Thousand USD | 281.793% |
| Bioxytran, Inc. | -3.82 Million USD | 90.387% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -597.608% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 85.084% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 98.976% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -716.047% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 86.588% |
| Neutra Corp. | -181.24 Thousand USD | -102.608% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 98.178% |
| PureTech Health plc | -11.62 Million USD | 96.842% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 98.178% |
| IXICO plc | -707 Thousand USD | 48.059% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 95.222% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 99.24% |
| CSL Limited | 4.73 Billion USD | 100.008% |
| Cellectis S.A. | -92.63 Million USD | 99.604% |